Endocyte: Endocyte Loss Narrows Amid Pending Acquisition

West Lafayette-based Endocyte Inc. (Nasdaq: ECYT) is reporting a third quarter net loss of $12.6 million, compared to a net loss of $23.3 million during the same period a year earlier. The biopharmaceutical company is in the midst of a proposed $2.1 billion acquisition by Switzerland-based Novartis AG, which is expected to close in the first half of next year. The deal is considered the largest of its kind ever for an Indiana life sciences company.